NasdaqGM:ARDXBiotechs
How Ardelyx’s Phase 3 IBSRELA Trial in Chronic Constipation Has Changed Its Investment Story At Ardelyx (ARDX)
Ardelyx recently dosed the first patient in ACCEL, a Phase 3, 26‑week, randomized, double‑blind, placebo‑controlled trial of IBSRELA (tenapanor) in about 700 adults with chronic idiopathic constipation, with topline data expected in the second half of 2027.
This program aims to broaden IBSRELA’s use beyond irritable bowel syndrome with constipation into a much larger chronic idiopathic constipation population, estimated at more than 34 million Americans.
We’ll now examine how this Phase 3...